Rheumatology Drugs Flashcards
What is Cosentyx®?
secukinumab
What is the MOA of secukinumab?
Cosentyx (secukinumab) is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
What is Taltz®?
ixekizumab
What is the target of dapirolizumab pegol?
What is the major study recently published about this medication?
Anti-CD40
Phase 3 PHOENYCS GO study (published 2024) - a 48 week study of SLE pts with moderate to severe disease who were on standard of care therapy who received either dapirolizumab or placebo - those receiving dapirolizumab had significant improvement in the BILAG scores at week 38.
Aside from rituximab, what is another anti-CD20 agent? In what trial was this recently used in SLE patients?
Obinutuzumab (Gazyava).
REGENCY Phase 3 trial enrolling patients with biopsy-proven lupus nephritis (class III or class IV proliferative disease with or without membranous disease) - all patients were taking a background of mycophenolate and prednisolone and they were either given obinutuzumab for 76 weeks. By the primary and secondary end-points, obinutuzumab was superior to placebo in addition to standard of care.
What is Bimekizumab? How does it work?
Binekizumab (Bimzelex) is a humanised anti-IL-17A and anti-IL-17F monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and ankylosing spondylitis.
Bimekizumab was FDA-approved in Oct 2023 for active moderate to severe plaque psoriasis not responding to or needing more than conventional therapy. Its uptake in Dermatology has been very strong. We have only recently (Sept ‘24) got approval for in the rheumatology world for bimekizumab for active psoriatic arthritis, active ankylosing spondylitis and active non-radiographic axial spondyloarthropathy.
The dosing in rheumatology is different to that used for active psoriasis patients - in rheumatology, we use 160mg subcut injection every 4 weeks (there is a pre-filled syringe and autoinjector). The approval is based on two big trials in psoriatic arthritis - the BE OPTIMAL and the BE COMPLETE trial, and 2 other big trials in the spondyloarthropathies (the MOBILE 1 and MOBILE 2 trials). The other takeaway from these trials is that the drug works equally well in those who are biologic naive and those who are biologic experienced.
